Bres, P. A century of progress in combating yellow fever. Bull. World Health Organ. 64, 775–786 (1986).
Wax, R. G. Manipulation of human history by microbes. Clin. Microbiol. Newsl. 29, 9–16 (2007).
Staples, J. E. & Monath, T. P. Yellow fever: 100 years of discovery. JAMA 300, 960–962 (2008).
Walter, R. C. J. & Agramonte, A. The etiology of yellow fever: an additional note. JAMA 36, 431–440 (1901).
Barrett, A. D. T. & Higgs, S. Yellow fever: a disease that has yet to be conquered. Annu. Rev. Entomol. 52, 209–229 (2007).
World Health Organization. Yellow fever https://www.who.int/news-room/fact-sheets/detail/yellow-fever (WHO, 2023).
Hansen, C. A. & Barrett, A. D. T. The present and future of yellow fever vaccines. Pharmaceuticals https://doi.org/10.3390/ph14090891 (2021).
Meier, K. C., Gardner, C. L., Khoretonenko, M. V., Klimstra, W. B. & Ryman, K. D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. https://doi.org/10.1371/journal.ppat.1000614 (2009).
Vasconcelos, P. F. C. & Monath, T. P. Yellow fever remains a potential threat to public health. Vector Borne Zoonotic Dis. 16, 566–567 (2016).
Orenstein, W. A., Offit, P. A., Edwards, K. M. & Plotkin, S. A. Plotkin’s Vaccines 8th edn (Elsevier, 2024).
Wang, H. J. et al. Development of a bicistronic yellow fever live attenuated vaccine with reduced neurovirulence and viscerotropism. Microbiol. Spectr. https://doi.org/10.1128/spectrum.02246-22 (2022).
Davis, E. H. et al. Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism. npj Vaccines https://doi.org/10.1038/s41541-022-00460-6 (2022).
Lee, E. & Lobigs, M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol. 82, 6024–6033 (2008).
Zhang, J. Y. et al. Amino acid changes in two viral proteins drive attenuation of the yellow fever 17D vaccine. Nat. Microbiol. https://doi.org/10.1038/s41564-025-02047-y (2025).
Nickells, J. et al. Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model. J. Virol. 82, 12510–12519 (2008).
Fernandez-Garcia, M. D. et al. Vaccine and wild-type strains of yellow fever virus engage distinct entry mechanisms and differentially stimulate antiviral immune responses. Mbio https://doi.org/10.1128/mBio.01956-15 (2016).
Chong, Z. et al. Multiple LDLR family members act as entry receptors for yellow fever virus. Nature https://doi.org/10.1038/s41586-025-09689-2 (2025).
Douam, F. & Ploss, A. Yellow fever virus: knowledge gaps impeding the fight against an old foe. Trends Microbiol. 26, 913–928 (2018).
Sack, L. M. et al. Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns. Cell https://doi.org/10.1016/j.cell.2018.02.037 (2018).
Li, S. et al. Gain-of-function genetic screening identifies the antiviral function of TMEM120A via STING activation. Nat. Commun. https://doi.org/10.1038/s41467-021-27670-1 (2022).
Pierson, T. C. et al. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 346, 53–65 (2006).
Herz, J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 29, 571–581 (2001).
Kim, D. H. et al. Human apolipoprotein E receptor 2—a novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271, 8373–8380 (1996).
Novak, S., Hiesberger, T., Schneider, W. J. & Nimpf, J. A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. J. Biol. Chem. 271, 27188 (1996).
Clark, L. E. et al. VLDLR and ApoER2 are receptors for multiple alphaviruses. Nature https://doi.org/10.1038/s41586-021-04326-0 (2022).
Meertens, L. et al. The TIM and TAM families of phosphatidylserine receptors mediate Dengue virus entry. Cell Host Microbe 12, 544–557 (2012).
Hirai, H. et al. Structural basis for ligand capture and release by the endocytic receptor ApoER2. EMBO Rep. 18, 982–999 (2017).
Li, M. et al. Rift valley fever virus and yellow fever virus in urine: a potential source of infection. Virol. Sin. 34, 342–345 (2019).
Pierson, T. C., Lazear H. M. & Diamond M. S. in Fields Virology Vol. 1 (eds Howley, P. M. & Knipe, D. M.) Ch. 9 (Wolters Kluwer, 2021).
Danet, L. et al. Midgut barriers prevent the replication and dissemination of the yellow fever vaccine. Plos Negl. Trop. Dis. https://doi.org/10.1371/journal.pntd.0007299 (2019).
Bellone, R., Mousson, L., Bohers, C., Mantel, N. & Failloux, A.B. Absence of transmission of vYF next generation yellow fever vaccine in mosquitoes. PLoS Negl. Trop. Dis. https://doi.org/10.1371/journal.pntd.0010930 (2022).
Mittler, E. et al. LRP8 is a receptor for tick-borne encephalitis virus. Nature https://doi.org/10.1038/s41586-025-09500-2 (2025).
Erickson, A. K. & Pfeiffer, J. K. Spectrum of disease outcomes in mice infected with YFV-17D. J. Gen. Virol. 96, 1328–1339 (2015).
Jiang, C. et al. PSGL-1 is an evolutionarily conserved antiviral restriction factor. Mbio 14, e0038723 (2023).
Read more about this post…
Credits: Source
Disclaimer
Serving 